| 2025年9月19日星期五丨 NO.1复宏汉霖CDK4/6抑制剂在中国获批新适应证 复宏汉霖宣布,创新型CDK4/6抑制剂枸橼酸伏维西利胶囊新增适应证的药品注册申请获得中国国家药品监督管理局(NMPA)批准。本次获批适应证为用于激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性(HR+/HER2-)局部晚期或转移性乳腺癌成人患者,与芳香化酶抑制剂联合使用作为初始内分泌治疗。此前,...
Source Link| 2025年9月19日星期五丨 NO.1复宏汉霖CDK4/6抑制剂在中国获批新适应证 复宏汉霖宣布,创新型CDK4/6抑制剂枸橼酸伏维西利胶囊新增适应证的药品注册申请获得中国国家药品监督管理局(NMPA)批准。本次获批适应证为用于激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性(HR+/HER2-)局部晚期或转移性乳腺癌成人患者,与芳香化酶抑制剂联合使用作为初始内分泌治疗。此前,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.